Omicron-specific Sinopharm COVID-19 vaccine candidates cleared for clinical trial in Hong kong
BEIJING, April 16 (Reuters) - COVID-19 vaccine candidates developed by a Sinopharm subsidiary and Sinovac Biotech (SVA.O) to target the Omicron variant were approved for clinical trials in Hong Kong, the companies said on Saturday
Other World News Videos
LIVE | Trump's Freedom 250 spectacle: Flyovers, fireworks and 'Salute to America'
'Reject those who see only America's sins!': VP JD Vance addresses the nation on America 250
'I'm asking a serious question!': Sen. Andy Kim grills USPS chief over legality of census pilot
'For 250 years America has..': JD Vance delivers remarks aboard USS Kearsarge in New York Harbor
'Who was the real Prez?': Autopen scandal explodes at ‘Biden cover-up’ hearing; Senators erupt
